Literature DB >> 7672669

A reliable cure for Helicobacter pylori infection?

D Y Graham1.   

Abstract

Entities:  

Mesh：

Year:  1995        PMID： 7672669      PMCID： PMC1382790          DOI： 10.1136/gut.37.1.154

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  6 in total

1.  In vivo susceptibility of Campylobacter pylori.

Authors:  D Y Graham; P D Klein; A R Opekun; K E Smith; R R Polasani; D J Evans; D G Evans; L C Alpert; P A Michaletz; H H Yoshimura
Journal:  Am J Gastroenterol       Date:  1989-03       Impact factor: 10.864

2.  Sample sizes for constructing confidence intervals and testing hypotheses.

Authors:  D R Bristol
Journal:  Stat Med       Date:  1989-07       Impact factor: 2.373

3.  Evolution of concepts regarding Helicobacter pylori: from a cause of gastritis to a public health problem.

Authors:  D Y Graham
Journal:  Am J Gastroenterol       Date:  1994-04       Impact factor: 10.864

4.  The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results.

Authors:  S N Goodman; J A Berlin
Journal:  Ann Intern Med       Date:  1994-08-01       Impact factor: 25.391

5.  Randomized study comparing 1 with 2 weeks of quadruple therapy for eradicating Helicobacter pylori.

Authors:  W A de Boer; W M Driessen; V P Potters; G N Tytgat
Journal:  Am J Gastroenterol       Date:  1994-11       Impact factor: 10.864

6.  Factors influencing the eradication of Helicobacter pylori with triple therapy.

Authors:  D Y Graham; G M Lew; H M Malaty; D G Evans; D J Evans; P D Klein; L C Alpert; R M Genta
Journal:  Gastroenterology       Date:  1992-02       Impact factor: 22.682
  6 in total
  9 in total

Review 1.  Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.

Authors:  H D Langtry; M I Wilde
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

Review 2.  One- or two-week triple therapy for Helicobacter pylori: questions of efficacy and inclusion of a dual therapy treatment arm.

Authors:  David Y Graham; Yoshio Yamaoka
Journal:  Gut       Date:  2007-07       Impact factor: 23.059

Review 3.  Recurrence of Helicobacter pylori infection after successful eradication: nature and possible causes.

Authors:  H X Xia; N J Talley; C T Keane; C A O'Morain
Journal:  Dig Dis Sci       Date:  1997-09       Impact factor: 3.199

4.  1976 and all that!--20 years of antisecretory therapy.

Authors:  A Garner; H Fadlallah; M E Parsons
Journal:  Gut       Date:  1996-12       Impact factor: 23.059

5.  How should we decide on the best regimen for eradicating Helicobacter pylori?

Authors:  V Savarino; S Vigneri
Journal:  BMJ       Date:  1995-09-02

6.  Prevalence of primary Helicobacter pylori resistance to metronidazole and clarithromycin in The Netherlands.

Authors:  A A van Zwet; W A de Boer; P M Schneeberger; J Weel; A R Jansz; J C Thijs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-11       Impact factor: 3.267

7.  One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea.

Authors:  C L Perng; J G Kim; H M El-Zimaity; M S Osato; D Y Graham
Journal:  Dig Dis Sci       Date:  1998-03       Impact factor: 3.199

8.  Appearance of a metronidazole-resistant Helicobacter pylori strain in an infected-ICR-mouse model and difference in eradication of metronidazole-resistant and -sensitive strains.

Authors:  S Matsumoto; Y Washizuka; Y Matsumoto; S Tawara; F Ikeda; Y Yokota; M Karita
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

9.  Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond.

Authors:  David Y Graham; Hong Lu; Yoshio Yamaoka
Journal:  Drugs       Date:  2008       Impact factor: 9.546
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.